TigerResearch/tigerbot-earning-plugin huggingface dataset:
项目|期末余额|期初余额
库存现金|49,517.00|79,368.70
银行存款|912,041,712.10|1,014,956,246.20
其他货币资金|15,580,327.72|1,332,198.88
合计|927,671,556.82|1,016,367,813.78
其中:存放在境外的款项总额|2,146.60|1,239,103.65
因抵押、质押或冻结等对使用有限制的款项总额|15,437,178.27|1,236,599.28
1、期末其他货币资金余额15,580,327.72 元,其中:票据保证金余额14,840,288.00元,证券资金账户余额731,516.16元,有赞、支付宝等电子支付账户余额为8,523.56元。
2、除上述票据保证金外,银行存款中存在596,890.27元因银行系统升级缺失系统留存的授权业务办理人员信息而受到支付监管,存在使用有限制的情形。截至2023 年3 月8 日,公司该账户已解除支付监管。
项目|期末余额|期初余额
以公允价值计量且其变动计入当期损益的金融资产|340,679,204.35|239,915,280.92
其中:||
股票投资|229,048,754.61|239,915,280.92
理财产品|60,090,000.00|0.00
结构性存款|51,540,449.74|0.00
指定以公允价值计量且其变动计入当期损益的金融资产|0.00|0.00
其中:||
|0.00|0.00
合计|340,679,204.35|239,915,280.92
项目|期末余额|期初余额
|0.00|0.00
合计|0.00|0.00
项目|期末余额|期初余额
银行承兑票据|655,887,819.92|298,920,093.45
商业承兑票据|46,055,671.33|0.00
合计|701,943,491.25|298,920,093.45
类别|期末余额|||||期初余额||||
|账面余额||坏账准备||账面价值|账面余额||坏账准备||账面价值
|金额|比例|金额|计提比例||金额|比例|金额|计提比例|
按单项计提坏账准备的应收票据|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
其中:||||||||||
按组合计提坏账准备的应收票据|701,943,491.25|100.00%|0.00|0.00%|701,943,491.25|298,920,093.45|100.00%|0.00|0.00%|298,920,093.45
其中:||||||||||
银行承兑汇票及信用证组合1|414,210,229.26|59.01%|0.00|0.00%|414,210,229.26|173,658,907.63|58.10%|0.00|0.00%|173,658,907.63
银行承兑汇票及信用证组合2|241,677,590.66|34.43%|0.00|0.00%|241,677,590.66|125,261,185.82|41.90%|0.00|0.00%|125,261,185.82
银行承兑汇票及信用证组合3|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
银行承兑汇票及信用证组合4|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
商业承兑汇票组合1|46,055,671.33|6.56%|0.00|0.00%|46,055,671.33|0.00|0.00%|0.00|0.00%|0.00
商业承兑汇票组合2|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
商业承兑汇票组合3|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
商业承兑汇票组合4|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
合计|701,943,491.25|100.00%|0.00|0.00%|701,943,491.25|298,920,093.45|100.00%|0.00|0.00%|298,920,093.45
名称|期末余额|||
|账面余额|坏账准备|计提比例|计提理由
合计|0.00|0.00||
名称|期末余额||
|账面余额|坏账准备|计提比例
银行承兑汇票及信用证组合1|414,210,229.26|0.00|
银行承兑汇票及信用证组合2|241,677,590.66|0.00|
商业承兑汇票组合1|46,055,671.33|0.00|
合计|701,943,491.25|0.00|
类别|期初余额|本期变动金额||||期末余额
||计提|收回或转回|核销|其他|
合计|0.00|0.00|0.00|0.00|0.00|0.00
项目|期末已质押金额
银行承兑票据|0.00
商业承兑票据|0.00
合计|0.00
项目|期末终止确认金额|期末未终止确认金额
银行承兑票据|123,877,035.93|179,401,575.19
商业承兑票据|0.00|0.00
合计|123,877,035.93|179,401,575.19
项目|期末转应收账款金额
商业承兑票据|0.00
合计|0.00
单位名称|应收票据性质|核销金额|核销原因|履行的核销程序|款项是否由关联交易产生
合计||0.00|||
类别|期末余额|||||期初余额||||
|账面余额||坏账准备||账面价值|账面余额||坏账准备||账面价值
|金额|比例|金额|计提比例||金额|比例|金额|计提比例|
按单项计提坏账准备的应收账款|496,171.92|0.09%|496,171.92|100.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
其中:||||||||||
按组合计提坏账准备的应收账款|534,282,482.99|99.91%|32,701,849.60|6.12%|501,580,633.39|524,486,785.92|100.00%|31,526,674.91|6.01%|492,960,111.01
其中:||||||||||
账龄组合|534,282,482.99|99.91%|32,701,849.60|6.12%|501,580,633.39|524,486,785.92|100.00%|31,526,674.91|6.01%|492,960,111.01
关联方组合|0.00|0.00%|0.00|0.00%|0.00|0.00|0.00%|0.00|0.00%|0.00
合计|534,778,654.91|100.00%|33,198,021.52|6.21%|501,580,633.39|524,486,785.92|100.00%|31,526,674.91|6.01%|492,960,111.01
|账面余额|坏账准备|计提比例|计提理由
六盘水市钟山区仲康民安综合医院|208,479.00|208,479.00|100.00%|预计难以收回款项
其他公司|287,692.92|287,692.92|100.00%|预计难以收回款项
合计|496,171.92|496,171.92||
名称|期末余额||
|账面余额|坏账准备|计提比例
1 年以内(含1 年)|515,008,252.38|25,750,468.44|5.00%
1 至2 年|13,111,264.34|1,311,126.44|10.00%
2 至3 年|1,045,423.11|522,711.56|50.00%
3 年以上|5,117,543.16|5,117,543.16|100.00%
3 至4 年|1,725,286.42|1,725,286.42|100.00%
4 至5 年|440,808.54|440,808.54|100.00%
5 年以上|2,951,448.20|2,951,448.20|100.00%
合计|534,282,482.99|32,701,849.60|
账龄|账面余额
1 年以内(含1 年)|515,134,349.30
1 至2 年|13,148,425.34
2 至3 年|1,378,337.11
3 年以上|5,117,543.16
3 至4 年|1,725,286.42
4 至5 年|440,808.54
5 年以上|2,951,448.20
合计|534,778,654.91
类别|期初余额|本期变动金额||||期末余额
||计提|收回或转回|核销|其他|
按单项计提|0.00|496,171.92|0.00|0.00|0.00|496,171.92
按组合计提||||||
其中:账龄组合|31,526,674.91|1,452,564.76|159,936.72|105,904.39|11,548.96|32,701,849.60
关联方|0.00|0.00|0.00|0.00|0.00|0.00
组合||||||
合计|31,526,674.91|1,948,736.68|159,936.72|105,904.39|11,548.96|33,198,021.52
单位名称|收回或转回金额|收回方式
合计|0.00|
项目|核销金额
实际核销的应收账款|105,904.39
单位名称|应收账款性质|核销金额|核销原因|履行的核销程序|款项是否由关联交易产生
合计||0.00|||
本期无重要的应收账款核销。
单位名称|应收账款期末余额|占应收账款期末余额合计数的比例|坏账准备期末余额
客户A|24,456,792.07|4.57%|1,222,839.60
客户B|21,868,414.92|4.09%|1,093,420.75
客户C|16,723,044.84|3.13%|836,152.24
客户D|14,842,774.33|2.78%|742,138.72
客户E|14,223,304.00|2.66%|711,165.20
合计|92,114,330.16|17.23%|
项目|期末余额|期初余额
银行承兑汇票|30,000.00|575,334.80
合计|30,000.00|575,334.80
账龄|期末余额||期初余额|
|金额|比例|金额|比例
1 年以内|86,248,153.90|98.04%|92,392,122.82|94.68%
1 至2 年|1,027,281.38|1.17%|3,925,749.40|4.02%
2 至3 年|118,548.73|0.13%|571,238.45|0.59%
3 年以上|578,800.18|0.66%|691,722.33|0.71%
合计|87,972,784.19||97,580,833.00|
单位名称|与本公司关系|金额(元)|账龄|尚未结算原因
 A公司|非关联方|12,593,941.92|1年以内|业务未完结
 B公司|非关联方|8,301,315.28|1年以内|业务未完结
 C公司|非关联方|7,917,229.72|1年以内|业务未完结
 D公司|非关联方|5,388,220.00|1年以内|业务未完结
 E公司|非关联方|4,751,947.79|1年以内|业务未完结
合计||38,952,654.71||
项目|期末余额|期初余额
应收利息|0.00|0.00
应收股利|0.00|0.00
其他应收款|22,647,141.30|4,465,950.40
合计|22,647,141.30|4,465,950.40
项目|期末余额|期初余额
定期存款|0.00|0.00
委托贷款|0.00|0.00
债券投资|0.00|0.00
合计|0.00|0.00
借款单位|期末余额|逾期时间|逾期原因|是否发生减值及其判断依据
合计|0.00|||
项目(或被投资单位)|期末余额|期初余额
合计|0.00|0.00
项目(或被投资单位)|期末余额|账龄|未收回的原因|是否发生减值及其判断依据
合计|0.00|||
款项性质|期末账面余额|期初账面余额
业务借支|199,929.76|256,301.50
保证金|2,015,897.27|1,969,045.84
社会保险费|800,874.05|778,050.38
公积金|965,585.64|841,244.44
水电费|10,626.34|247.52
技术转让款|850,000.00|0.00
服务费|217,752.34|253,289.73
结算往来款|195,272.75|744,490.68
物流赔偿款|0.00|4,129.72
押金|76,350.00|204,148.70
设备款|884,522.21|879,584.55
应收退伙对价|19,300,000.00|0.00
其他|1,199,028.62|702,431.16
合计|26,715,838.98|6,632,964.22
应收退伙对价是指公司本期退出联营企业北京中军正和正信众生医药产业投资合伙企业(有限合伙)未收回的余款。截至2023年2月20日,公司已收回此款项。
坏账准备|第一阶段|第二阶段|第三阶段|合计
|未来12 个月预期信用损失|整个存续期预期信用损失(未发生信用减值)|整个存续期预期信用损失(已发生信用减值)|
2022 年1 月1 日余额|514,660.14|0.00|1,652,353.68|2,167,013.82
2022 年1 月1 日余额||||
在本期||||
——转入第二阶段|0.00|0.00|0.00|0.00
——转入第三阶段|-29,000.00|0.00|29,000.00|0.00
——转回第二阶段|0.00|0.00|0.00|0.00
——转回第一阶段|0.00|0.00|0.00|0.00
本期计提|1,502,565.00|0.00|505,066.00|2,007,631.00
本期转回|55,578.96|0.00|240.00|55,818.96
本期转销|24,000.00|0.00|27,481.33|51,481.33
本期核销|0.00|0.00|0.00|0.00
其他变动|3,202.11|0.00|-4,555.26|-1,353.15
2022 年12月31 日余额|1,905,444.07|0.00|2,163,253.61|4,068,697.68
账龄|账面余额
1 年以内(含1 年)|23,477,892.30
1 至2 年|153,330.66
2 至3 年|1,835,157.46
3 年以上|1,249,458.56
3 至4 年|78,000.00
4 至5 年|121,143.52
5 年以上|1,050,315.04
合计|26,715,838.98
类别|期初余额|本期变动金额||||期末余额
||计提|收回或转回|核销|其他|
按单项计提|520,340.00|476,066.00|0.00|0.00|0.00|996,406.00
按组合计提||||||
其中:账龄组合|1,646,673.82|1,531,565.00|55,818.96|51,481.33|-1,353.15|3,072,291.68
关联方组合|0.00|0.00|0.00|0.00|0.00|0.00
合计|2,167,013.82|2,007,631.00|55,818.96|51,481.33|-1,353.15|4,068,697.68
单位名称|转回或收回金额|收回方式
合计|0.00|——
项目|核销金额
实际核销的其他应收款|51,481.33
单位名称|其他应收款性质|核销金额|核销原因|履行的核销程序|款项是否由关联交易产生
合计||0.00|||
本期无重要的其他应收款核销。
单位名称|款项的性质|期末余额|账龄|占其他应收款期末余额合计数的比例|坏账准备期末余额
北京中军正和正信众生医药产业投资合伙企业(有限合伙)|应收退伙对价|19,300,000.00|1 年以内|72.24%|965,000.00
海南卓科制药有限公司|技术转让款|850,000.00|1 年以内|3.18%|42,500.00
广州福珀斯医疗设备有限公司|保证金|673,392.20|2-3 年|2.52%|336,696.10
广东康朗医药有限公司|其他|520,340.00|2-3 年|1.95%|520,340.00
安徽欣益文化科技有限公司|其他|476,066.00|1 年以内|1.78%|476,066.00
合计||21,819,798.20||81.67%|2,340,602.10
单位名称|政府补助项目名称|期末余额|期末账龄|预计收取的时间、金额及依据
||0.00||
项目|期末余额|||期初余额||
|账面余额|存货跌价准备或合同履约成本减值准备|账面价值|账面余额|存货跌价准备或合同履约成本减值准备|账面价值
原材料|297,742,670.66|1,603,443.25|296,139,227.41|273,562,419.27|5,231,870.92|268,330,548.35
在产品|44,716,542.72|123,660.67|44,592,882.05|45,357,727.19|0.00|45,357,727.19
库存商品|118,725,017.18|2,661,239.26|116,063,777.92|114,774,793.33|3,444,185.55|111,330,607.78
周转材料|0.00|0.00|0.00|0.00|0.00|0.00
消耗性生物资产|56,101.43|0.00|56,101.43|320.00|0.00|320.00
合同履约成本|1,204,661.65|0.00|1,204,661.65|464,581.06|0.00|464,581.06
发出商品|22,999,167.31|0.00|22,999,167.31|26,714,975.86|0.00|26,714,975.86
合计|485,444,160.95|4,388,343.18|481,055,817.77|460,874,816.71|8,676,056.47|452,198,760.24
项目|期初余额|本期增加金额||本期减少金额||期末余额
||计提|其他|转回或转销|其他|
原材料|5,231,870.92|1,529,974.27|0.00|5,158,401.94|0.00|1,603,443.25
在产品|0.00|123,660.67|0.00|0.00|0.00|123,660.67
库存商品|3,444,185.55|1,060,736.83|0.00|1,825,787.12|17,896.00|2,661,239.26
周转材料|0.00|0.00|0.00|0.00|0.00|0.00
消耗性生物资产|0.00|0.00|0.00|0.00|0.00|0.00
合同履约成本|0.00|0.00|0.00|0.00|0.00|0.00
合计|8,676,056.47|2,714,371.77|0.00|6,984,189.06|17,896.00|4,388,343.18
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
合计|0.00|0.00|0.00|0.00|0.00|0.00
项目|变动金额|变动原因
合计|0.00|——
项目|本期计提|本期转回|本期转销/核销|原因
合计|0.00|0.00|0.00|——
项目|期末账面余额|减值准备|期末账面价值|公允价值|预计处置费用|预计处置时间
西湖宿舍土地及地上建筑物|1,572,232.97|0.00|1,572,232.97|8,142,080.00|0.00|2023 年内
合计|1,572,232.97|0.00|1,572,232.97|8,142,080.00|0.00|
为配合东莞市石龙镇生物医药产业基地建设,东莞市石龙镇人民政府与本公司签订收回协议,以8,142,080.00 元的价格收回本公司持有的石龙镇西湖宿舍土地及地上建筑物。根据协议约定,公司预计2023年内完成移交工作。
项目|期末余额|期初余额
一年内到期的债权投资|0.00|0.00
一年内到期的其他债权投资|0.00|0.00
一年内到期的大额存单|151,753,424.67|0.00
合计|151,753,424.67|0.00
债权项目|期末余额||||期初余额|||
|面值|票面利率|实际利率|到期日|面值|票面利率|实际利率|到期日
合计|0.00||||0.00|||
项目|期末余额|期初余额
合同取得成本|0.00|0.00
应收退货成本|0.00|0.00
大额存单|0.00|40,000,000.00
预缴企业所得税|10,176,347.78|8,801,375.16
待认证增值税进项税|683,607.25|12,736,990.60
留抵进项税|6,789,357.19|7,017,059.81
预缴工会经费|0.00|4,765.21
合计|17,649,312.22|68,560,190.78
坏账准备|第一阶段|第二阶段|第三阶段|合计
|未来12 个月预期信用损失|整个存续期预期信用损失(未发生信用减值)|整个存续期预期信用损失(已发生信用减值)|
2022 年1 月1 日余额|0.00|0.00|0.00|0.00
2022 年1 月1 日余额在本期||||
——转入第二阶段|0.00|0.00|0.00|0.00
——转入第三阶段|0.00|0.00|0.00|0.00
——转回第二阶段|0.00|0.00|0.00|0.00
——转回第一阶段|0.00|0.00|0.00|0.00
本期计提|0.00|0.00|0.00|0.00
本期转回|0.00|0.00|0.00|0.00
本期转销|0.00|0.00|0.00|0.00
本期核销|0.00|0.00|0.00|0.00
其他变动|0.00|0.00|0.00|0.00
2022 年12月31 日余额|0.00|0.00|0.00|0.00
项目|期初余额|应计利息|本期公允价值变动|期末余额|成本|累计公允价值变动|累计在其他综合收益中确认的损失准备|备注
合计|0.00|0.00|0.00|0.00|0.00|0.00|0.00|
其他债权项目|期末余额||||期初余额|||
|面值|票面利率|实际利率|到期日|面值|票面利率|实际利率|到期日
合计|0.00||||0.00|||
项目|期末余额|||期初余额|||折现率区间
|账面余额|坏账准备|账面价值|账面余额|坏账准备|账面价值|
融资租赁款|0.00|0.00|0.00|0.00|0.00|0.00|0
其中:未实现融资收益|0.00|0.00|0.00|0.00|0.00|0.00|0
分期收款销售商品|0.00|0.00|0.00|0.00|0.00|0.00|0
分期收款提供劳务|0.00|0.00|0.00|0.00|0.00|0.00|0
合计|0.00|0.00|0.00|0.00|0.00|0.00|
坏账准备|第一阶段|第二阶段|第三阶段|合计
|未来12 个月预期信用损失|整个存续期预期信用损失(未发生信用减|整个存续期预期信用损失(已发生信用减|
||值)|值)|
2022 年1 月1 日余额|0.00|0.00|0.00|0.00
2022 年1 月1 日余额在本期||||
——转入第二阶段|0.00|0.00|0.00|0.00
——转入第三阶段|0.00|0.00|0.00|0.00
——转回第二阶段|0.00|0.00|0.00|0.00
——转回第一阶段|0.00|0.00|0.00|0.00
本期计提|0.00|0.00|0.00|0.00
本期转回|0.00|0.00|0.00|0.00
本期转销|0.00|0.00|0.00|0.00
本期核销|0.00|0.00|0.00|0.00
其他变动|0.00|0.00|0.00|0.00
2022 年12月31 日余额|0.00|0.00|0.00|0.00
被投资单位|期初余额(账面价值)|本期增减变动||||||||期末余额(账面价值)|减值准备期末余额
||追加投资|减少投资|权益法下确认的投资损益|其他综合收益调整|其他权益变动|宣告发放现金股利或利润|计提减值准备|其他||
一、合营企业|||||||||||
小计|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00
二、联营企业|||||||||||
北京中军正和正信众生医药|75,458,920.62|0.00|74,749,413.43|-709,507.19|0.00|0.00|0.00|0.00|0.00|0.00|0.00
产业投资合伙企业(有限合伙)|||||||||||
常州远景眼科医药科技有限公司|538,603.60|0.00|0.00|1,219,901.83|0.00|0.00|0.00|0.00|0.00|1,758,505.43|0.00
湖北众鸿企业管理咨询有限公司|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00
北京众弘力健康管理有限公司|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00
东莞市众明健康管理服务有限公司|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00|0.00
四川众点健康管理有限公司|270,124.04|0.00|0.00|357,303.71|0.00|0.00|0.00|0.00|0.00|627,427.75|0.00
东莞市众佳品牌推广服务有限公司|71,314.20|0.00|0.00|-71,314.20|0.00|0.00|0.00|0.00|0.00|0.00|0.00
东莞市众浩健康管理服务有限公司|1,133,575.52|0.00|0.00|65,765.47|0.00|0.00|0.00|0.00|0.00|1,199,340.99|0.00
东莞市众翔健康管理服务有限公司|544,505.88|0.00|0.00|-500,965.99|0.00|0.00|0.00|0.00|0.00|43,539.89|0.00
南宁市众泷健康服务有限公司|0.00|170,000.00|0.00|98,216.71|0.00|0.00|0.00|0.00|0.00|268,216.71|0.00
广东柏众医药科技有限公司|0.00|1,200,000.00|0.00|-828,563.86|0.00|0.00|0.00|0.00|0.00|371,436.14|0.00
小计|78,017,043.86|1,370,000.00|74,749,413.43|-369,163.52|0.00|0.00|0.00|0.00|0.00|4,268,466.91|0.00
合计|78,017|1,370,|74,749|-|0.00|0.00|0.00|0.00|0.00|4,268,|0.00
|,043.86|000.00|,413.43|369,163.52||||||466.91|
项目|期末余额|期初余额
非交易性权益工具投资|127,831,248.93|120,007,151.13
合计|127,831,248.93|120,007,151.13
项目名称|确认的股利收入|累计利得|累计损失|其他综合收益转入留存收益的金额|指定为以公允价值计量且其变动计入其他综合收益的原因|其他综合收益转入留存收益的原因
广东华南新药创制有限公司|0.00|0.00|0.00|0.00|不以出售为目的|不适用
成都博远嘉昱创业投资合伙企业(有限合伙)|0.00|63,578,148.74|0.00|0.00|不以出售为目的|不适用
东莞市大城区民营投资有限公司|0.00|0.00|0.00|0.00|不以出售为目的|不适用
其他权益工具投资均为以公允价值计量且其变动计入其他综合收益的权益工具投资。根据相关协议,本公司与其他投资者按比例分担投资风险、分享投资收益。
项目|期末余额|期初余额
以公允价值计量且变动计入当期损益的金融资产||
其中:权益工具投资|26,865,000.00|30,000,000.00
债务工具投资|865,000.00|8,000,000.00
合计|27,730,000.00|38,000,000.00
项目|房屋、建筑物|土地使用权|在建工程|合计
一、账面原值||||
1.期初余额|29,997,776.35|14,531,204.21|0.00|44,528,980.56
2.本期增加金额|22,454,816.91|588,210.01|0.00|23,043,026.92
(1)外购|0.00|0.00|0.00|0.00
(2)存货\固定资产\在建工程转入|22,454,816.91|0.00|0.00|22,454,816.91
(3)企业合并增加|0.00|0.00|0.00|0.00
(4)无形资产转入|0.00|588,210.01|0.00|588,210.01
3.本期减少金额|2,935,293.76|518,694.12|0.00|3,453,987.88
(1)处置|0.00|0.00|0.00|0.00
(2)其他转出|0.00|0.00|0.00|0.00
(3)转入固定资产/无形资产|2,935,293.76|518,694.12|0.00|3,453,987.88
4.期末余额|49,517,299.50|14,600,720.10|0.00|64,118,019.60
二、累计折旧和累计摊销||||
1.期初余额|9,665,235.63|2,598,767.36|0.00|12,264,002.99
2.本期增加金额|7,426,332.93|542,153.18|0.00|7,968,486.11
(1)计提或摊销|1,388,278.57|354,981.17|0.00|1,743,259.74
(2)固定资产/无形资产转入|6,038,054.36|187,172.01|0.00|6,225,226.37
3.本期减少金额|628,678.51|98,418.24|0.00|727,096.75
(1)处置|0.00|0.00|0.00|0.00
(2)其他转出|0.00|0.00|0.00|0.00
(3)转入固定资产/无形资产|628,678.51|98,418.24|0.00|727,096.75
4.期末余额|16,462,890.05|3,042,502.30|0.00|19,505,392.35
三、减值准备||||
1.期初余额|0.00|0.00|0.00|0.00
2.本期增加金额|0.00|0.00|0.00|0.00
(1)计提|0.00|0.00|0.00|0.00
||||
3.本期减少金额|0.00|0.00|0.00|0.00
(1)处置|0.00|0.00|0.00|0.00
(2)其他转|0.00|0.00|0.00|0.00
出||||
||||
4.期末余额|0.00|0.00|0.00|0.00
四、账面价值||||
1.期末账面价值|33,054,409.45|11,558,217.80|0.00|44,612,627.25
2.期初账面价值|20,332,540.72|11,932,436.85|0.00|32,264,977.57
项目|期末余额|期初余额
固定资产|549,220,430.46|538,583,146.56
固定资产清理|0.00|0.00
合计|549,220,430.46|538,583,146.56
项目|房屋建筑物|构筑物及其他辅助设施|机器设备|运输设备|办公及其他设备|合计
一、账面原值:||||||
1.期初余额|418,907,095.11|55,607,688.93|414,198,539.23|11,865,713.64|142,738,885.05|1,043,317,921.96
2.本期增加金额|41,668,201.94|18,487,439.62|27,923,443.90|995,460.78|24,284,900.21|113,359,446.45
(1)购置|0.00|366,972.45|8,994,806.80|992,760.78|13,594,390.83|23,948,930.86
(2)在建工程转入|38,732,908.18|18,012,364.39|17,808,180.84|0.00|5,050,341.63|79,603,795.04
(3)企业合并增加|0.00|0.00|0.00|0.00|0.00|0.00
(4)投资性房地产转入|2,935,293.76|0.00|0.00|0.00|0.00|2,935,293.76
(5)其他变动|0.00|108,102.78|1,120,456.26|2,700.00|5,640,167.75|6,871,426.79
3.本期减少金额|26,044,679.53|2,341,030.88|15,788,717.89|658,880.00|4,610,122.32|49,443,430.62
(1)处置或报废|0.00|0.00|9,976,041.75|658,880.00|587,791.77|11,222,713.52
(2)转入投资性房地产|21,115,296.31|1,339,520.60|0.00|0.00|0.00|22,454,816.91
(3)转入在建工程|1,143,083.22|1,001,510.28|151,239.34|0.00|2,405,394.71|4,701,227.55
(4)合并范围减少|0.00|0.00|0.00|0.00|407,586.68|407,586.68
(5)其他变动|3,786,300.00|0.00|5,661,436.80|0.00|1,209,349.16|10,657,085.96
4.期末余额|434,530,617.52|71,754,097.67|426,333,265.24|12,202,294.42|162,413,662.94|1,107,233,937.79
二、累计折旧||||||
1.期初余额|152,118,455.91|17,396,797.16|244,447,362.82|8,652,276.26|82,119,883.25|504,734,775.40
2.本期增加金额|18,221,375.75|5,975,209.80|30,982,274.49|917,459.47|17,158,647.22|73,254,966.73
(1)计提|17,592,697.24|5,883,761.87|30,982,274.49|914,894.47|15,336,829.94|70,710,458.01
(2)投资性房地产转入|628,678.51|0.00|0.00|0.00|0.00|628,678.51
(3)其他变动|0.00|91,447.93|0.00|2,565.00|1,821,817.28|1,915,830.21
3.本期减少金额|9,139,060.67|270,987.06|8,280,524.12|625,936.00|1,659,726.95|19,976,234.80
(1)处置或报废|0.00|0.00|6,358,069.37|625,936.00|554,932.81|7,538,938.18
(2)转入投资性房地产|5,870,139.36|167,915.00|0.00|0.00|0.00|6,038,054.36
(3)转入在建工程|685,850.00|103,072.06|91,681.59|0.00|687,654.45|1,568,258.10
(4)合并范围减少|0.00|0.00|0.00|0.00|332,082.64|332,082.64
(5)其他变动|2,583,071.31|0.00|1,830,773.16|0.00|85,057.05|4,498,901.52
4.期末余额|161,200,770.99|23,101,019.90|267,149,113.19|8,943,799.73|97,618,803.52|558,013,507.33
三、减值准备||||||
1.期初余额|0.00|0.00|0.00|0.00|0.00|0.00
2.本期增加金额|0.00|0.00||0.00|0.00|0.00
(1)计提|0.00|0.00|0.00|0.00|0.00|0.00
||||||
3.本期减少金额|0.00|0.00|0.00|0.00|0.00|0.00
(1|0.00|0.00|0.00|0.00|0.00|0.00
)处置或报废||||||
||||||
4.期末余额|0.00|0.00|0.00|0.00|0.00|0.00
四、账面价值||||||
1.期末账面价值|273,329,846.53|48,653,077.77|159,184,152.05|3,258,494.69|64,794,859.42|549,220,430.46
2.期初账面价值|266,788,639.20|38,210,891.77|169,751,176.41|3,213,437.38|60,619,001.80|538,583,146.56
项目|账面原值|累计折旧|减值准备|账面价值|备注
|0.00|0.00|0.00|0.00|
项目|期末账面价值
机器设备|4,424.77
办公及其他设备|1,838,696.37
合计|1,843,121.14
项目|账面价值|未办妥产权证书的原因
|0.00|
项目|期末余额|期初余额
在建工程|82,030,705.56|56,469,222.05
工程物资|0.00|0.00
合计|82,030,705.56|56,469,222.05
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
设备安装工程|7,698,022.58|0.00|7,698,022.58|4,673,941.43|0.00|4,673,941.43
建筑工程|0.00|0.00|0.00|9,600,794.34|0.00|9,600,794.34
鼎湖厂区改造|0.00|0.00|0.00|500,990.11|0.00|500,990.11
中药提取车间建设项目|74,066,682.98|0.00|74,066,682.98|39,434,892.74|0.00|39,434,892.74
多颗粒系统制剂平台|266,000.00|0.00|266,000.00|2,258,603.43|0.00|2,258,603.43
合计|82,030,705.56|0.00|82,030,705.56|56,469,222.05|0.00|56,469,222.05
项目名称|预算数|期初余额|本期增加金额|本期转入固定资产金额|本期其他减少金额|期末余额|工程累计投入占预算比例|工程进度|利息资本化累计金额|其中:本期利息资本化金额|本期利息资本化率|资金来源
中药提取车间建设项目|236,870,000.00|39,434,892.74|80,527,734.47|45,895,944.23|0.00|74,066,682.98|50.71%|50.71%|0.00|0.00|0.00%|其他
多颗粒系统制剂平台|25,000,000.00|2,258,603.43|1,628,942.80|3,621,546.23|0.00|266,000.00|78.63%|78.63%|0.00|0.00|0.00%|其他
合计|261,870,000.00|41,693,496.17|82,156,677.27|49,517,490.46|0.00|74,332,682.98|||0.00|0.00|0.00%|
中药提取车间项目包含上年度的中药生产车间项目。
项目|本期计提金额|计提原因
合计|0.00|--
项目|房屋及建筑物|土地使用权|合计
一、账面原值|||
1.期初余额|8,100,582.01|1,413,206.45|9,513,788.46
2.本期增加金额|1,500,835.07|0.00|1,500,835.07
(1)新增租赁|1,500,835.07|0.00|1,500,835.07
3.本期减少金额|0.00|0.00|0.00
|||
4.期末余额|9,601,417.08|1,413,206.45|11,014,623.53
二、累计折旧|||
1.期初余额|2,565,184.30|760,957.33|3,326,141.63
2.本期增加金额|2,007,428.64|108,708.24|2,116,136.88
(1)计提|2,007,428.64|108,708.24|2,116,136.88
|||
3.本期减少金额|0.00|0.00|0.00
(1)处置|0.00|0.00|0.00
|||
4.期末余额|4,572,612.94|869,665.57|5,442,278.51
三、减值准备|||
1.期初余额|0.00|0.00|0.00
2.本期增加金额|0.00|0.00|0.00
(1)计提|0.00|0.00|0.00
|||
3.本期减少金额|0.00|0.00|0.00
(1)处置|0.00|0.00|0.00
|||
4.期末余额|0.00|0.00|0.00
四、账面价值|||
1.期末账面价值|5,028,804.14|543,540.88|5,572,345.02
2.期初账面价值|5,535,397.71|652,249.12|6,187,646.83
项目|土地使用权|专利权|非专利技术|专利使用费|软件|合计
一、账面原值||||||
1.期初余额|152,077,502.85|83,712,909.33|124,657,947.54|1,000,000.00|40,671,573.55|402,119,933.27
2.本期增加金额|518,694.12|0.00|15,151,134.59|0.00|9,288,036.03|24,957,864.74
(1)购置|0.00|0.00|0.00|0.00|9,288,036.03|9,288,036.03
(2)内部研发|0.00|0.00|15,151,134.59|0.00|0.00|15,151,134.59
(3)企业合并增加|0.00|0.00|0.00|0.00|0.00|0.00
(4)投资性房地产转入|518,694.12|0.00|0.00|0.00|0.00|518,694.12
3.本期减少金额|1,161,810.01|0.00|0.00|0.00|0.00|1,161,810.01
(1)处置|0.00|0.00|0.00|0.00|0.00|0.00
(2)转入投资性房地产|588,210.01|0.00|0.00|0.00|0.00|588,210.01
(3)其他变动|573,600.00|0.00|0.00|0.00|0.00|573,600.00
4.期末余额|151,434,386.96|83,712,909.33|139,809,082.13|1,000,000.00|49,959,609.58|425,915,988.00
二、累计摊销||||||
1.期初余额|30,893,511.15|31,202,251.31|64,763,507.76|970,238.08|12,983,036.70|140,812,545.00
2.本期增加金额|3,494,760.33|5,280,874.47|12,429,001.15|29,761.92|3,863,572.31|25,097,970.18
(1)计提|3,396,342.09|5,280,874.47|12,429,001.15|29,761.92|3,863,572.31|24,999,551.94
(2)投资性房地产转入|98,418.24|0.00|0.00|0.00|0.00|98,418.24
3.本期减少金额|391,767.73|0.00|0.00|0.00|0.00|391,767.73
(1)处置|0.00|0.00|0.00|0.00|0.00|0.00
(2)转入投资性房地产|187,172.01|0.00|0.00|0.00|0.00|187,172.01
(3)其他变动|204,595.72|0.00|0.00|0.00|0.00|204,595.72
4.期末余额|33,996,503.75|36,483,125.78|77,192,508.91|1,000,000.00|16,846,609.01|165,518,747.45
三、减值准备||||||
1.期初余额|0.00|0.00|0.00|0.00|0.00|0.00
2.本期增加金额|0.00|0.00|0.00|0.00|0.00|0.00
(1)计提|0.00|0.00|0.00|0.00|0.00|0.00
||||||
3.本期减少金额|0.00|0.00|0.00|0.00|0.00|0.00
(1)处置|0.00|0.00|0.00|0.00|0.00|0.00
||||||
4.期末余额|0.00|0.00|0.00|0.00|0.00|0.00
四、账面价值||||||
1.期末账面价值|117,437,883.21|47,229,783.55|62,616,573.22|0.00|33,113,000.57|260,397,240.55
2.期初账面价值|121,183,991.70|52,510,658.02|59,894,439.78|29,761.92|27,688,536.85|261,307,388.27
本期末通过公司内部研发形成的无形资产占无形资产余额的比例13.28%。
项目|期初余额|本期增加金额|||本期减少金额|||期末余额
||内部开发支出|其他|合作开发|确认为无形资产|转入当期损益|其他|
 ZSYM002|38,446,395.06|1,155,014.06|0.00|1,364,674.70|0.00|0.00|0.00|40,966,083.82
 ZSYM004|34,653,525.68|86,560.64|0.00|781,820.95|0.00|0.00|0.00|35,521,907.27
 ZSYM005|96,276,379.10|4,792,943.43|0.00|17,742,557.12|0.00|0.00|0.00|118,811,879.65
 ZSYM006|36,978,573.10|2,453,160.93|0.00|1,781,849.33|0.00|0.00|0.00|41,213,583.36
 ZSYM007|41,236,853.64|3,556,131.42|0.00|0.00|0.00|0.00|0.00|44,792,985.06
ZSYM009|56,923,049.63|3,302,272.73|0.00|3,225,587.45|0.00|0.00|0.00|63,450,909.81
羧甲司坦片技术开发|2,672,977.34|22,027.66|0.00|-141,509.43|2,553,495.57|0.00|0.00|0.00
盐酸利托君技术开发|38,816.23|0.00|0.00|0.00|0.00|38,816.23|0.00|0.00
氯雷他定系列|9,698,246.58|135,397.01|0.00|322,173.60|10,155,817.19|0.00|0.00|0.00
环孢素眼用乳剂|3,168,854.04|2,136,667.32|0.00|1,438,926.23|0.00|0.00|0.00|6,744,447.59
注射用多西他赛聚合物胶束|4,482,518.78|435,543.55|0.00|949,481.27|0.00|0.00|0.00|5,867,543.60
 RCYM001|9,000,000.00|0.00|0.00|0.00|0.00|0.00|0.00|9,000,000.00
硫糖铝口服混悬液的研发|690,393.62|790,787.07|0.00|396,226.40|0.00|0.00|0.00|1,877,407.09
注射用紫杉醇聚合物胶束的研发|5,407,276.66|533,690.63|0.00|883,954.33|0.00|0.00|0.00|6,824,921.62
非诺贝特胶囊的仿制药一致性评价|145,862.95|419,727.36|0.00|520,697.80|0.00|0.00|0.00|1,086,288.11
利福平胶囊一致性评价|2,021,691.54|335,481.23|0.00|84,649.06|2,441,821.83|0.00|0.00|0.00
 RAY001|10,000,000.00|0.00|0.00|0.00|0.00|0.00|0.00|10,000,000.00
 RAY002|18,000,000.00|0.00|0.00|0.00|0.00|0.00|0.00|18,000,000.00
 RAY003|10,000,000.00|11,115,816.61|0.00|120,510,075.25|0.00|0.00|0.00|141,625,891.86
瑞巴派特片的研发|0.00|678,550.12|0.00|1,967,955.71|0.00|0.00|0.00|2,646,505.83
合计|379,841,4|31,949,77|0.00|151,829,1|15,151,13|38,816.23|0.00|548,430,3
|13.95|1.77||19.77|4.59|||54.67
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少||期末余额
||企业合并形成的|其他|处置|其他|
云南益康药业有限公司|6,949,110.48|0.00|0.00|0.00|0.00|6,949,110.48
广东先强药业有限公司|915,862,010.22|0.00|0.00|0.00|0.00|915,862,010.22
广东逸舒制药股份有限公司|162,669,444.46|0.00|0.00|0.00|0.00|162,669,444.46
广州糖网医疗科技有限公司|8,918,065.52|0.00|0.00|0.00|0.00|8,918,065.52
合计|1,094,398,630.68|0.00|0.00|0.00|0.00|1,094,398,630.68
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少||期末余额
||计提|其他|处置|其他|
云南益康药业有限公司|0.00|0.00|0.00|0.00|0.00|0.00
广东先强药业有限公司|783,665,680.97|0.00|0.00|0.00|0.00|783,665,680.97
广东逸舒制药股份有限公司|93,188,687.10|0.00|0.00|0.00|0.00|93,188,687.10
广州糖网医疗科技有限公司|8,918,065.52|0.00|0.00|0.00|0.00|8,918,065.52
合计|885,772,433.59|0.00|0.00|0.00|0.00|885,772,433.59
1、公司于2013 年以25,000,000.00元的对价购买了云南益康药业有限公司(以下简称“益康药业”)51.46%的股权,公司于购买日取得益康药业可辨认净资产的公允价值份额18,050,889.52 元。合并成本大于合并中取得的益康药业可辨认净资产公允价值份额的差额为6,949,110.48 元,确认为合并资产负债表中的商誉。
2、公司于2015 年以1,269,970,000.00元的对价购买了广东先强药业有限公司(以下简称“先强药
业”)97.69%的股权,公司于购买日取得先强药业可辨认净资产的公允价值份额354,107,989.78元。合并成本大于合并中取得的先强药业可辨认净资产公允价值份额的差额为915,862,010.22元,确认为合并资产负债表中的商誉。
3、公司于2018 年以402,635,065.46元收购了广东逸舒制药股份有限公司(以下简称“逸舒制药”)80.526%的股权,公司于购买日取得逸舒制药可辨认净资产的公允价值份额239,965,621.00元。合并成本大于合并中取得的逸舒制药可辨认净资产公允价值份额的差额为162,669,444.46 元,确认为合并资产负债表中的商誉。
4、公司于2018 年以15,740,000.00元收购了广州糖网医疗科技有限公司(以下简称“糖网科技”)
90.00%的股权,公司于购买日取得糖网科技可辨认净资产的公允价值份额6,821,934.48元。合并成本大于合并中取得的糖网科技可辨认净资产公允价值份额的差额为8,918,065.52元,确认为合并资产负债表中的商誉。
1、资产组的认定
公司认定存在商誉的子公司单独产生现金流量,将各子公司整体作为一个资产组。各资产组账面价值包括经营性长期资产。本期末商誉所在资产组与购买日、以前年度商誉减值测试时所确定的资产组一致。
2、商誉减值测试的过程与方法、结论
对商誉所在各资产组的可收回金额以预计未来现金流量的现值来确定。其中:
(1)对于逸舒制药,根据《广东逸舒制药股份有限公司中药提取车间建设项目可行性研究报告》,资产组所在单位中药提取业务预计在2029 年达产,因此本次详细预测期至2029 年,2030 年进入稳定期。公司在对逸舒制药的商誉进行减值测试时,参考了金证(上海)资产评估有限公司出具的金证评报字【2023】第0082号《广东众生药业股份有限公司拟对收购广东逸舒制药股份有限公司股权形成的商誉进行减值测试所涉及的商誉相关资产组可收回金额资产评估报告》的评估结果。
(2)对于先强药业,公司在对逸舒制药的商誉进行减值测试时,参考了金证(上海)资产评估有限公司出具的金证评报字【2023】第0083号《广东众生药业股份有限公司拟对收购广东先强药业有限公司股权形成的商誉进行减值测试所涉及的商誉相关资产组可收回金额资产评估报告》的评估结果。
(3)除上述外,其他公司资产组的预计未来现金流量基于管理层编制的未来5 年财务预算来确定,超过5年财务预算之后年份的现金流量保持稳定,公司根据历史经验及对市场发展的预测确定关键数据。
项目|云南益康药业有限公司|广东先强药业有限公司|广东逸舒制药股份有限公司|广州糖网医疗科技有限公司
商誉账面价值1|6,949,110.48|132,196,329.25|69,480,757.36|-
未确认归属于少数股东权益的商誉价值2|6,554,796.40|3,125,944.52|16,802,874.46|-
包含未确认归属于少数股东权益的商誉价值3=1+2|13,503,906.88|135,322,273.77|86,283,631.82|-
资产组账面价值4|60,767,345.20|112,856,032.67|322,063,608.55|-
包含商誉的资产组账面价值5=3+4|74,271,252.08|248,178,306.44|408,347,240.37|-
资产组可回收金额6|104,000,000.00|291,000,000.00|418,000,000.00|-
商誉减值损失7|-|-|-|-
归属于少数股东的商誉减值8|-|-|-|-
归属于本公司的商誉减值9=7-8|-|-|-|-
公司|预测期|预测期复合增长率|稳定期增长率|利润率|折现率
云南益康药业有限公司|2023-2027 年|6.54%|持平|根据预测的收入、成本、费用等计算|10.91%
广东先强药业有限公司|2023-2027 年|8.48%|持平||11.34%
广东逸舒制药股份有限公司|2023-2029 年|14.22%|持平||11.74%
公司期末对以上商誉进行减值测试,测试结果表明商誉未发生减值。
项目|期初余额|本期增加金额|本期摊销金额|其他减少金额|期末余额
装修费|6,563,433.14|1,290,416.97|2,052,135.17|0.00|5,801,714.94
电子邮箱升级项目|149,880.49|0.00|38,267.28|0.00|111,613.21
合计|6,713,313.63|1,290,416.97|2,090,402.45|0.00|5,913,328.15